<DOC>
	<DOC>NCT00002374</DOC>
	<brief_summary>To examine the efficacy of saquinavir SGC (soft gel capsules) in combination with other antiretrovirals in HIV-1 infected patients currently treated with saquinavir HGC (hard gel capsules) measured by the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment.</brief_summary>
	<brief_title>A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients</brief_title>
	<detailed_description>Eligible patients will be stratified by HIV-1 RNA level into 2 populations: 1) &gt;= 5,000-30,000 HIV-1 RNA, 2) &gt; 30,000 HIV-1 RNA. All patients will be randomized to 1 of 3 treatment arms: Arm A - Saquinavir soft gel capsules (SQV SGC) + 2 new nucleoside analogs (reverse transcriptase inhibitors [RTIs]), Arm B - SQV SGC + nelfinavir + stavudine (d4T) or a new RTI, or Arm C - SQV SGC + ritonavir + d4T or a new RTI. All patients will undergo plasma HIV-1 RNA determinations, CD4 lymphocyte counts, hematology and chemistry blood work at baseline, weeks 4, 8, 12, 16 and 24.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Documented HIV infection. CD4 &gt; 100 cells/mm3. Saquinavir HGCexperienced patients (&gt;= 3 months cumulative therapy). Required: &gt;= 3 months cumulative saquinavir HGC therapy.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA, Viral</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>